Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.

Lung Cancer

Patients With Cancer Who Vape Are at Significant Risk for EVALI

Bryant Furlow

February 4, 2020

A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.

Renal Cell Carcinoma

Getting More Specific About Adjuvant Therapy Effects in Kidney Cancer

Bryant Furlow

December 27, 2019

Results from the phase 3 S-TRAC clinical trial suggested that for selected young and otherwise healthy patients, toxicities of sunitinib are manageable.

ASH 2019

Tirabrutinib Shows Promise in Waldenström Macroglobulinemia

Bryant Furlow

December 11, 2019

The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).

Biomarker detects early-stage lung cancer.

ASH 2019

Inotuzumab Ozogamicin Shows Clinical Efficacy in Relapsed Pediatric B-ALL

Bryant Furlow

December 11, 2019

Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).

ASH 2019

Epigenetic Drug CPI-0610 Called Clinically Active, Tolerable in Myelofibrosis

Bryant Furlow

December 9, 2019

“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”

ASH 2019

Frontline Bendamustine Plus Rituximab Deemed “Highly Effective” in Waldenström Macroglobulinemia

Bryant Furlow

December 9, 2019

There was no benefit observed with the use of rituximab in the maintenance setting in Waldenström macroglobulinemia.

Tosedostat with cytarabine or decitabine induced complete remission in AML/MDS.

ASH 2019

CXCR4 Mutations Do Not Impact Progression-Free Survival in Waldenström Macroglobulinemia Patients Treated With Proteasome Inhibitors

Bryant Furlow

December 9, 2019

No detectable differences were found in major response rate at 6 months and 12 months between patients with and without CXCR4 mutations.

ASH 2019

Real-World Sequence Patterns of Novel Agents in CLL Described

Bryant Furlow

December 9, 2019

More than half of the patients with CLL included in the retrospective study first received a novel agent in the second-line setting.

Researchers conducted a meta-analysis of 4 studies examining prophylaxis with factor VIII or emicizumab for hemophilia A without inhibitors.

ASH 2019

Nonrelapse Mortality in B-Cell Lymphomas “Should Be Reported Prospectively,” According to Researchers

Bryant Furlow

December 8, 2019

The researchers determined that in FAERS, a greater proportion of cytokine release syndrome occurred with axi-cel.

Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.

ASH 2019

Bridging Therapy Prior to CAR-T Is Not Recommended for All Patients With Lymphoma

Bryant Furlow

December 8, 2019

Researchers noted that bridging while awaiting CAR-T manufacturing may not be appropriate for all patients, and in some cases, bridging was associated with worse PFS and OS.

Next post in ASH 2019